Eikon Therapeutics, Inc. 8-K

What Happened
Eikon Therapeutics, Inc. announced on May 11, 2026 that it issued a press release reporting its financial results for the quarter ended March 31, 2026 and provided clinical and corporate updates. The company also updated its corporate presentation the same day. Both the press release and updated presentation were furnished with the SEC on Form 8‑K.

Key Details

• Filing date: May 11, 2026 (Form 8‑K Items 2.02 and 7.01).
• Quarter covered: Quarter ended March 31, 2026 (Q1 2026).
• Materials furnished: Press Release (Exhibit 99.1) and Corporate Presentation (Exhibit 99.2).
• Disclosure status: The materials are being “furnished,” not “filed,” meaning they are not subject to Section 18 liability under the Exchange Act or certain Securities Act liabilities.
• Signature: Report filed and signed on behalf of the company by CEO Roger M. Perlmutter, M.D., Ph.D.

Why It Matters
This 8‑K signals that Eikon released its latest quarterly financials and provided updates on clinical and corporate matters—information that can affect investor decisions. Retail investors should review the furnished press release and updated presentation (Exhibits 99.1 and 99.2) for the specific financial figures, cash position, and any clinical milestones or guidance. Note the disclosure is furnished (limited liability), so use the exhibits themselves as the primary source for detailed numbers and operational updates.